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1 
30 Abstract 
 
31 Background/Objectives 
 
32 There is no consensus on the definition of sarcopenic obesity (SO), resulting in inconsistent 
 
33 associations of SO with mortality risk. We aim to evaluate association of dual energy x-ray 
 
34 absorptiometry (DXA) SO models with mortality risk in a US adult population (≥50years). 
 
35 Subjects/Methods 
 
36 The study population consisted of 3,577 participants aged 50 years and older from the 1999-2004 
 
37 National Health and Nutrition and Examination Survey with mortality follow-up data through 
 
38 December 31, 2011. Difference in survival time in people with and without SO defined by three body 
 
39 composition DXA models (Model 1: body composition phenotype model; Model 2: Truncal Fat Mass 
 
40 (TrFM)/Appendicular Skeletal Muscle Mass (ASM) ratio model; Model 3: Fat Mass (FM)/Fat Free 
 
41 Mass (FFM) ratio). The differences between the models were assessed by the acceleration failure 
 
42 time model, and expressed as time ratios (TR). 
 
43 Results 
 
44 Participants age 50–70years with SO had a significantly decreased survival time, according to the 
 
45 body composition phenotype model (TR: 0.92; 95%CI: 0.87–0.97), and TrFM/ASM ratio model (TR: 
 
46 0.88; 95%CI: 0.81–0.95). The FM/FFM ratio model did not detect significant differences in survival 
 
47 time. Participants with SO aged 70years and older did not have a significantly decreased survival 
 
48 time, according to all three models. 
 
49 Conclusions 
 
50 A SO phenotype increases mortality risk in people of age 50–70years, but not in people aged 70years 
 
51 and older. The application of the body composition phenotype and the TrFM/ASM ratio models may 
 
52 represent useful diagnostic approaches to improve the prediction of disease and mortality risk. 
 
53 
 
54 
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55 Introduction 
 
56 Body composition is influenced by different physiological and non-physiological factors such as 
 
57 aging, gender, diet and physical activity, or acute and chronic illnesses[1]. These factors contribute to 
 
58 shape the overall distribution of population body composition phenotypes as they are key risk 
 
59 factors, amongst others, for increased adiposity and loss of lean body mass [2-4] and aging may 
 
60 represent an important modifier of these reciprocal body composition changes[5]. The net result of 
 
61 these biological, lifestyle and demographic trends could be an increase in the prevalence of the 
 
62 sarcopenic obesity (SO) phenotype, defined as the co-occurrence of high adiposity and low lean 
 
63 body mass in the same individual[6]. 
 
64 Body Mass Index (BMI) is the most widely used indicator to assess adiposity. However, a limitation of 
 
65 BMI is its inability to distinguish the proportion of fat and lean body mass[7]. This limitation can be 
 
66 overcome using different body composition methods and dual energy x-ray absorptiometry (DXA) 
 
67 may offer the best compromise to cost, accuracy and reproducibility [8]. 
 
68 DXA is currently considered as one of the most accurate body composition methods for the 
 
69 assessment of SO[9]. However, there is no consensus as yet on the definitions of SO[9-11]. 
 
70 Consequently, the application of different definitions of SO has been an important limiting factor in 
 
71 trying to establish its predictive role for disease risk and mortality. Important drawbacks of many SO 
 
72 definitions are the lack of control for between-subject differences in body mass, use of young 
 
73 populations as reference groups and assessment of adiposity using anthropometric indexes (i.e., 
 
74 BMI, waist circumference). The consequences of these differences are the inconsistent association 
 
75 of SO with mortality in studies reporting significant[12-18] and non-significant associations[19, 20]. 
 
76 Novel DXA models for the assessment of SO and other body composition phenotypes have been 
 
77 proposed, which allow for the control of the confounding effects of age, sex and BMI[21, 22]. These 
 
78 models were developed from DXA data of the U.S. National Health and Nutrition Examination Survey 
 
79 (NHANES) 1999–2004. The aims of these analyses are to verify if these newly proposed DXA models 
 
80 are significant predictors of increased or decreased survival time in a US adult population (age 50 
 
81 years and older), if these models predict survival time better than body mass index (BMI), and, 
 
82 finally, to obtain more insights into the association between SO and mortality risk. 
 
83 
 
84 Methods 
 
85 NHANES 
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86 Data  were  obtained  from  the  NHANES 1999-2004. The  NHANES is a survey  of  the  non- 
 
87 institutionalized civilian resident population of the United States. A complex, multistage probability 
 
88 sampling design was used to select a representative sample of 14,200 participants[23]. The NHANES 
 
89 data on mortality for public use are available continuously for the entire 1999–2004 period. 
 
90 Mortality data were available from the date of survey participation to December 31, 2011[24] and 
 
91 the follow-up period ranged between 7 and 12 years. Mortality status is determined by conducting a 
 
92 probabilistic pairing between NHANES and records of death certificates from the National Death 
 
93 Index. Detailed information about NHANES and the mortality data can also be found elsewhere[23, 
 
94 25]. For this analysis, participants weighing more than 136kg, taller than 1.96meters (n=3,707), 
 
95 below 50 years of age (n=6,306), who died in less than 24 months after the baseline survey (n=121), 
 
96 and with missing data for household income level (n=470), average daily physical activity level 
 
97 (n=10), education level (n=9), and mortality status (n=7; total participants with missing data: n=489) 
 
98 were excluded from the analysis. The final sample consisted of 3,577 participants. 
 
99 DXA 
 
100 Body composition assessment was undertaken by DXA (Hologic QDR 4500A)[24]. Participants were 
 
101 not eligible for a DXA scan if they were pregnant, weighed more than 136kg and if they were taller 
 
102 than 1.96meters. In addition, participants were not eligible if they had been exposed to radiographic 
 
103 contrast material in the past 7 days or nuclear medicine in the past 3 days[24]. Complete DXA data 
 
104 were obtained from 80% of the eligible participants[25]. DXA data incompleteness was related to 
 
105 age, BMI, weight and height, and multiple imputation of the missing data was performed by the 
 
106 National Center for Health Statistics (NCHS). Five completed data files containing both the non- 
 
107 missing and imputed DXA data values were created[25]. 
 
108 BMI and DXA-models of body composition phenotypes 
 
109 Nutritional status and body composition were defined to analyse if subgroups based on these 
 
110 variables have an increased or decreased survival time. Nutritional status was defined by BMI (body 
 
111 weight/height2), and categorized for analysis as BMI <25.0kg/m2, 25.0–30.0kg/m2 and ≥30.0kg/m2. 
 
112 Body composition and SO were assessed by three different models based on DXA data[21, 22]. These 
 
113 three approaches have in common that they divide people into groups based on specific cut-points 
 
114 of muscle and fat mass. The cut-points are defined from age-standardised reference curves stratified 
 
115 by BMI and gender. The reference curves were developed from non-imputed NHANES 1999-2004 
 
116 DXA data of 13,236 participants above 18 years. The first approach, FM/FFM model, was based on 
 
117 the ratio between total fat mass (FM) and total fat free mass (FFM)[22]. The cut-off points of the 
 
118 reference curves for this approach were as follows: a ratio below the 15th centile, in the 15th-85th 
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119 centile, in the 85th-95th centile or above the 95th centile. The group with a FM/FFM ratio above the 
 
120 95th centile are considered as the SO group. The second approach, BC phenotype model, divides 
 
121 people in four different body composition phenotypes based on having low adiposity (LA) or high 
 
122 adiposity (HA) and low muscle mass (LM) or high muscle mass (HM)[21]. Participants were defined 
 
123 as having low or high adiposity when the fat mass index (total fat mass/height2) was below or above 
 
124 the 50th percentile of the reference curve. The same applies for low or high muscle mass, but then 
 
125 with reference curves of the appendicular skeletal muscle index (lean soft tissue of the arms and 
 
126 legs/height2). The group with HA and LM are considered as the SO group. The third, and most 
 
127 specific approach at the regional anatomic level, is the TrFM/ASM model. This approach was based 
 
128 on the ratio between truncal fat mass (TrFM) and appendicular skeletal muscle mass (ASM)[22], and 
 
129 similar to the FM/FFM model approach. The only difference was in the body components used for 
 
130 the calculation of the ratio. Assessment of body composition, according to the approaches 
 
131 mentioned above, were performed with an automated toolkit which can be made available upon 
 
132 request to the corresponding author (MS). Detailed information about the body composition models 
 
133 has been published previously[21, 22]. 
 
134 Covariates 
 
135 All covariates were self-reported. Ethnicity was classified as non-Hispanic white, Mexican American, 
 
136 non-Hispanic black or other ethnicity. Education level is the highest grade or level of school 
 
137 completed or the highest degree received, and classified as an education level lower than high 
 
138 school, high school, or higher than high school. The smoking status of participants was divided in 
 
139 smokers and non-smokers. Participant were classified as smoker if they regularly (some days or 
 
140 every day) smoked cigarettes, cigars or pipe or if they chewed tobacco. Average daily physical 
 
141 activity was classified as participants sits a lot; stands or walks a lot; lift light loads or climbs stairs or 
 
142 hills often; or does heavy work or carries heavy loads. 
 
143 Statistical analysis 
 
144 Descriptive statistics are expressed as mean ± standard error (continuous variables) or as 
 
145 percentages (categorical variables). Accelerated Failure Time (AFT) models were used to determine 
 
146 the association between time-to-event (e.g. mortality) and: (1) BMI; and, (2) the three body 
 
147 composition models. The AFT models are parametric models that assume a specific distribution, but 
 
148 do not require the assumption of proportional hazards (i.e. for Cox regression, which was not upheld 
 
149 in the data)[26]. Five different AFT models were fit assuming different distributions for the baseline 
 
150 hazard  function  (i.e.  Weibull,  exponential,  Gamma,  log-logistic  and  log-normal)  and  model 
 
151 performance compared fit using the Akaike Information Criterion (AIC) and Bayesian Information 
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152 Criterion (BIC). A final model assuming the log-normal distribution best fitted the data for the BMI 
 
153 and each of the three DXA-models of body composition phenotypes. If stratified analysis were 
 
154 performed the log-logistic distribution fitted best for participants aged 50 to 70 years, and the 
 
155 exponential distribution for participants aged 70 years and older. Outcomes are expressed as time 
 
156 ratios (TR) with 95% confidence intervals (95%CI). Age at death or the year 2011 was used as the 
 
157 time-scale with age at baseline survey used as the entry time[27]. Both uni-variable and 
 
158 multivariable models adjusting for sex, ethnicity, education level, household income level, smoking 
 
159 status and average daily physical activity were run  to test the association between body 
 
160 composition, defined by each model, with survival time. For each model, the reference group 
 
161 included those participants with a body composition that was assumed healthiest, i.e. low fat mass 
 
162 and high muscle mass. All statistical analyses were performed using the survey procedure of STATA 
 
163 version 14.2, which accounts for the complex sample design and DXA multiple imputation procedure 
 
164 of the NHANES dataset. 
 
165 Results 
 
166 Baseline characteristics of the sample are shown in Table 1. The total study population consisted of 
 
167 3,577 participants of 50 years and older, of which 15.4% were deceased in 2011. The subgroup of 
 
168 participants aged 50 to 69 years consisted of 2,424 participants, of which 8.4% were deceased in 
 
169 2011. The subgroup of participants of 70 years and older consisted of 1,153 participants, of which 
 
170 39.4% were deceased in 2011. The baseline characteristics of the 610 participants excluded from the 
 
171 analyses, because of missing data or deceased within 24 months after the baseline survey, are 
 
172 shown in Table 1 of the Online Supplementary Material. Overall, participants had similar 
 
173 characteristics for age, BMI, socio-demographic factors and prevalence of body composition 
 
174 phenotypes to the population included in the main analysis. 
 
175 The association between BMI category and survival years is shown in Table 2. There was no 
 
176 significant association between BMI and survival years for all participants. The same was observed 
 
177 for the subgroup analysis of the age groups 50 to 70 years and 70 years and older. 
 
178 In Table 3 the association between the FM/FFM model and survival is shown. There is no significant 
 
179 association for participants 50 years and older with a certain FM/FFM ratio and survival years. The 
 
180 same was observed for the subgroup analysis of the participants 50–70 years. In the subgroup 
 
181 analysis of the participants 70 years and older the participants with a FM/FFM ratio in the 15th-85th 
 
182 centile (TR: 1.53; 95%CI: 1.01–2.33) had a significant longer survival in comparison with the 
 
183 reference group. 
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184 The association between BC phenotype model and survival years is shown in Table 4. Participants 50 
 
185 years and older with LA-LM (TR: 0.95; 95%CI: 0.92–0.99) and HA-LM (SO, TR: 0.96; 95%CI: 0.92–0.99) 
 
186 had a significantly shorter survival compared to the participants with a LA-HM. The association 
 
187 became stronger in the subgroup analysis for participants aged 50-70 years with LA-LM (TR: 0.93; 
 
188 95% CI: 0.88–0.98) and HA-LM (SO, TR: 0.92; 95%CI: 0.87–0.97). In addition, participants with a HA- 
 
189 HM had a significant shorter survival compared to the participants with LA-HM (TR: 0.95; 95%CI: 
 
190 0.90–1.00). In the subgroup analysis for the participants aged 70 years and older the direction of the 
 
191 association changed. The participants with HA-HM (TR: 1.42; 95%CI: 1.07–1.89) survived significantly 
 
192 longer compared to the group with LA-HM. 
 
193 The association between TrFM/ASM model and survival years is shown in Table 5. There is no 
 
194 significant association for participants 50 years and older with TrFM/ASM ratio and survival years 
 
195 when adjusted for confounders. In the subgroup analysis the participants 50 to 70 years with a 
 
196 TrFM/ASM ratio in the 85th-95th centile (TR: 0.91; 95%CI: 0.84–0.99) and above the 95th centile (SO, 
 
197 TR: 0.88; 95%CI: 0.81–0.95) had a significantly shorter survival compared to the participants with a 
 
198 TrFM/ASM ratio below the 15th centile. In the subgroup analysis of the participants 70 years and 
 
199 older the direction of the association changed. Participants with a TrFM/ASM ratio in the 15th-85th 
 
200 (TR: 1.43; 95%CI: 1.14–1.79) had a significantly longer survival in comparison with the reference 
 
201 group. 
 
202 Discussion 
 
203 This study showed that BMI did not predict increased or decreased survival time in adults of 50 years 
 
204 and older. We showed for the first time that the DXA based BC phenotype and TrFM/ASM models 
 
205 significantly  predicted  survival  time.  However,  the  association  was  age-dependent  as  the 
 
206 participants with SO was associated with lower survival time in participants of 50 – 70 years, but not 
 
207 in participants older than 70 years of age. 
 
208 Specifically, significant differences in survival time were found between the body composition 
 
209 groups identified by the BC phenotype and the TrFM/ASM models. Therefore, these two models 
 
210 outperform BMI and the FM/FFM ratio model for the prediction of survival time in this population. 
 
211 The performance of the BC phenotype model could be explained by the use of ASM cut offs for the 
 
212 identification of sarcopenia and possibly a better discrimination of the body composition classes 
 
213 across the four different body composition phenotypes (i.e., HA-HM, LA-HM, LA-LM, HA-LM). The 
 
214 significant association of the TrFM/ASM model with survival time may be explained by the inclusion 
 
215 of measures of central adiposity and skeletal muscle mass; therefore, it could represent a more 
 
216 informative model based on the stronger link of these two components with the pathogenesis of 
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217 cardiovascular and metabolic diseases. ASM is a proxy measure of metabolic control, functional 
 
218 performance and physical disability[28-30] and loss of ASM is associated with poorer metabolic 
 
219 control and increased mortality as well as impaired quality of life[31]. 
 
220 We found that the association between SO and survival time were different in two age groups. The 
 
221 SO group aged 50 to 70 years had the lowest survival if defined by the BC phenotype model and 
 
222 TrFM/ASM ratio model. The SO group aged 70 years and older was instead not associated with a 
 
223 decreased survival time according to both models. The significant association of SO with increased 
 
224 mortality risk in the age group 50-70 years confirmed results found in other studies[12-18] . 
 
225 A recent study used the same NHANES 1999-2004 dataset to evaluate the association between SO 
 
226 and risk of overall mortality[18]. SO was defined by gender specific cut-off points for ASM and FM 
 
227 and adopted a diagnostic approach similar to our BC phenotype model. However, the two analyses 
 
228 were different for the choice of age cut offs (≥50 years vs ≥60 years) and stratification of the 
 
229 analyses (age- vs gender-stratified). A mid-life cut off point for age (≥50 years) was chosen for our 
 
230 analyses based on the capacity of our models to account for age in the identification of body 
 
231 composition phenotypes and considering mid-life as a critical life stage where ill health becomes the 
 
232 major cause of death, and the number of mortality events progressively increases [32]. In addition, 
 
233 several other studies exploring the association between body composition and health outcomes 
 
234 have used the same age cut off point[16, 33-41], and one of them conducted the same age-stratified 
 
235 analysis (<70y and ≥70 years) to evaluate the association between SO and mortality  [16]. 
 
236 Furthermore, we used AFT models (with age as time scale and age at baseline survey as entry time) 
 
237 to evaluate the association of SO with survival time since the proportional hazard assumptions were 
 
238 not met.  Despite the methodological differences, Batsis et al. [18] also observed a significant 
 
239 increase in mortality risk associated with SO (only in men) and the association was stronger for low 
 
240 lean body mass independent from adiposity. This result could be explained by the age-dependent 
 
241 effect of adiposity on risk of mortality that we observed in our age-stratified analysis. 
 
242 Other studies did not assess SO using DXA, but they used mid arm circumference[12, 17], or muscle 
 
243 function (walking speed[13]; hand grip/knee extensor strength[14-16]) to define sarcopenia. Excess 
 
244 adiposity was defined by anthropometric measurements including BMI[13, 14, 16] or WC[12, 15, 17]. 
 
245 However, the comparison of results from the various studies is also complicated by the differences 
 
246 in baseline age, sex distribution and duration of follow up; three studies included male participants 
 
247 only with age between 45 to 79 years and follow up range between 6 and 30 years[12, 14, 17]. Other 
 
248 studies included both middle aged and older men and women with age ranges between 50 and 91 
 
249 years and follow up duration between 5 and 33 years[15, 16] and in one study participants aged 
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250 between 65 and 102 years which were followed for 6 years[13]. Despite these differences, all these 
 
251 studies reported a significant association of sarcopenia or SO with mortality risk and our results are 
 
252 in line with these studies. Only one study[16] explored this age-interaction and, similar to our 
 
253 results, reported an increased mortality risk in obese and normal-weight participants with low 
 
254 handgrip strength in the 50-69 age group whereas overweight and obese participants aged 70 years 
 
255 and older with high handgrip strength had significantly lower mortality than normal-weight 
 
256 participants. This reversed prediction of adiposity for disease and mortality risk as age increases is a 
 
257 documented observation in epidemiological studies[16, 42-45]. The “adiposity-age paradox” is based 
 
258 on the notion that excess adiposity is one of the causal steps in the pathogenesis of cardiovascular 
 
259 and metabolic diseases at younger age but this predictive capacity progressively disappears as 
 
260 people age with excess adiposity becoming a protective factor[46]. 
 
261 A strength of this study is the large sample size of 3,577 participants and that body composition was 
 
262 analysed with DXA, which is currently the preferred method for body composition assessment based 
 
263 on the accuracy, repeatability and costs. In addition, the new proposed DXA models allowed to 
 
264 control for the confounding effect of age, sex and BMI on the assessment of the body composition 
 
265 phenotypes. In addition, in the survival analysis age was used as time scale instead of time on study. 
 
266 We also excluded individuals who died in the first two years of follow up to minimise the influence of 
 
267 severe illnesses on body composition and mortality at baseline. A limitation of this study is that 
 
268 people taller than 1.96m and heavier than 136kg were excluded from the analysis, since these 
 
269 people were not eligible for a DXA scan. A consequence of this is that it may not be fully 
 
270 representative of other, more extreme body composition phenotypes, such as individuals with 
 
271 morbid obesity. A potential limitation of our approach to identify SO cases is that it is based on the 
 
272 assessment of muscle mass without taking into consideration measures of muscular function as 
 
273 recommended in recent guidelines[47, 48]. These recommendations follow from findings that the 
 
274 important components of sarcopenia, low skeletal muscle mass and low skeletal muscle function, 
 
275 are not always directly associated and need to be identified separately. Although the assessment of 
 
276 muscular function is key to assess disease and mortality risk, our models aim primarily at improving 
 
277 the sensitivity of DXA-derived measurements of body composition for disease risk prediction. Future 
 
278 studies need to identify to what extent muscle function is able to improve mortality risk prediction 
 
279 based on our body composition models. Our current analysis advanced knowledge in the field by 
 
280 demonstrating a greater sensitivity of the body composition phenotype model and the TrFM/ASM 
 
281 ratio to predict mortality risk and observed that the sensitivity of the models is age-dependent. 
 
282 Future research is warranted to evaluate whether the addition of muscular function to the body 
 
283 composition phenotype and the TrFM/ASM ratio models may improve disease and mortality risk 
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284 prediction. Another limitation is that body composition was only measured at baseline, and the 
 
285 covariates of the analysis were self-reported. Additionally, the follow-up period was relatively short 
 
286 (7–12 years); however, this was the first study that used the novel DXA models and, even with this 
 
287 relatively short follow-up time, a significant association was found between body composition and 
 
288 mortality risk. 
 
289 In conclusion, the body composition phenotype model and the TrFM/ASM ratio model are sensitive 
 
290 significant predictors of survival. The preferred model, for future research, should depend on the 
 
291 research question. In addition, SO increases mortality risk in people of 50–70 years, but not in 
 
292 people of 70 years and older. In this group a relatively high FM and high muscle mass seem to be 
 
293 beneficial. More research is needed into the understanding of age-related differences in the 
 
294 association between body composition and mortality. 
 
295 
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Tables 
 
Table 1: Baseline characteristics of a representative US adult population of 50 years and older. 
 
 Participants 50+ Participants 50-70 Participants 70+ 
 years years years 
Participants, na 3,577 2,424 1,153 
    
Men, % 48.6 50.7 41.3 
    
Age at survey, mean (SE) 61.8 (0.2) 57.6 (0.2) 76.2 (0.1) 
    
Decedents, % 15.4 8.4 39.4 
    
Ethnicity    
    
Non-Hispanic white, % 79.1 77.7 84.1 
    
Mexican American, % 3.9 4.2 2.9 
    
Non-Hispanic black, % 8.2 8.7 6.7 
    
Ethnicity other, % 8.8 9.5 6.3 
    
Education level    
    
< High school, % 22.3 19.1 33.1 
    
High school, % 26.3 25.0 30.7 
    
> High school, % 51.4 55.9 36.2 
    
Household income level    
    
< $20.000, % 20.1 16.1 33.9 
    
$20.000-$65.000, % 49.0 48.0 52.3 
    
> $65.000, % 30.9 35.9 13.8 
    
Smoker, % 19.6 22.6 9.3 
    
Average daily physical activity    
    
Sits a lot during the day, % 25.8 5.3 27.5 
    
Stands or walks a lot during the day, % 55.1 54.2 58.4 
    
Lifts light loads during the day, % 14.8 15.4 12.7 
    
Does heavy work or carries heavy loads, % 4.3 5.1 1.4 
    
BMI    
    
< 18.5 kg/m2, % 0.2 0.1 0.6 
    
18.5 - 25.0 kg/m2, % 26.8 25.6 30.6 
    
25.0 - 30.0 kg/m2, % 40.1 39.0 44.0 
    
≥ 30.0 kg/m2, % 32.9 35.3 24.8 
    
Body composition phenotypesb, c    
    
LA-HM, % 23.4 23.2 23.9 
    
LA-LM, % 25.7 26.1 24.4 
    
HA-HM, % 26.9 27.4 25.3 
    
HA-LM, % 24.0 23.4 26.4 
    
TrFM/ASM centilesb, d    
    
<15th centile, % 12.4 12.0 13.9 
    
15-85th centile, % 71.9 72.4 70.3 
    
85-95th centile, % 9.9 9.9 9.9 
    
≥95 centile, % 5.8 5.7 5.9 
    
FM/FFM centilesb, e    
    
<15th centile, % 13.2 13.0 14.4 
    
 
15-85th centile, % 70.6 71.2 68.7 
    
85-95th centile, % 10.4 10.1 11.4 
    
≥95 centile, % 5.7 5.6 5.5 
 
Complex survey design is taken into account for calculating the baseline characteristics, unless stated otherwise. a Real 
observations, complex survey design is not taken into account. b Multiple imputed data. c LA is low adiposity, HA is high 
adiposity, LM is low adiposity and HM is high muscle mass. d TrFM is truncal fat mass, ASM is appendicular skeletal muscle 
mass, FM is fat mass and FFM is fat free mass. The groups are formed based on specific body composition ratio reference 
curves. 
Table 2: Time ratios (TR) for the association between BMI and survival years.  
 
 Participants ≥ 50 yearsa  Participants 50 - 70 yearsb Participants ≥ 70 yearsc 
          
 TR 95% CI p-value TR 95% CI p-value TR 95% CI p-value 
          
Crude model          
          
BMI < 25 kg/m2 1.00 . . 1.00 . . 1.00 . . 
          
BMI 25 – 30 kg/m2 1.03 1.00 - 1.06 0.06 1.04 0.99 - 1.08 0.10 1.01 0.99 - 1.03 0.48 
          
BMI ≥ 30 kg/m2 0.99 0.96 - 1.02 0.61 0.99 0.94 - 1.03 0.50 0.99 0.97 - 1.01 0.47 
          
Adjusted modeld          
          
BMI < 25 kg/m2 1.00 . . 1.00 . . 1.00 . . 
          
BMI 25 – 30 kg/m2 1.03 1.00 - 1.07 0.06 1.04 0.99 - 1.08 0.09 1.20 0.95 - 1.53 0.13 
          
BMI ≥ 30 kg/m2 0.99 0.96 - 1.03 0.65 0.99 0.94 - 1.04 0.62 1.22 0.92 - 1.61 0.16   
BMI is body mass index. Complex survey design is taken into account for calculating the TR. a Accelerated failure time model analysis with lognormal distribution. b Accelerated failure 
time model analysis with loglogistic distribution. c Accelerated failure time model analysis with exponential distribution. d Adjusted for sex, ethnicity, education level, household income 
level, smoking status and average daily physical activity.  
Table 3: Time ratios (TR) for the association between FM/FFM ratio and survival years. 
 
 Participants ≥ 50 yearsa  Participants 50 - 70 yearsb Participants ≥ 70 yearsc 
           
 TR 95% CI  p-value TR 95% CI p-value TR 95% CI p-value 
           
Crude model           
           
< 15th centile 1.00 .  . 1.00 . . 1.00 . . 
           
15-84th centile 1.02 0.98 - 1.06  0.31 1.01 0.96 - 1.07 0.68 1.20 0.91 - 1.59 0.18 
           
85-94th centile 1.01 0.96 - 1.06  0.70 0.98 0.92 - 1.05 0.58 1.44 0.94 - 2.19 0.09 
           
>95th centile 0.99 0.93 - 1.05  0.66 0.96 0.90 - 1.03 0.24 1.12 0.71 - 1.76 0.62 
           
Adjusted modeld           
           
< 15th centile 1.00 .  . 1.00 . . 1.00 . . 
           
15-84th centile 1.01 0.97 - 1.06  0.54 0.99 0.93 - 1.05 0.81 1.28 0.96 - 1.71 0.09 
           
85-94th centile 1.00 0.95 - 1.05  0.98 0.96 0.90 - 1.03 0.24 1.53 1.01 - 2.33 0.04 
           
>95th centile 1.00 0.94 - 1.06  0.96 0.96 0.89 - 1.04 0.35 1.31 0.82 - 2.09 0.26 
            
FM is fat mass and FFM is fat free mass. The groups are formed based on reference curves for the ratio between FM and FFM. Complex survey design is taken into account for calculating the 
TR. a Accelerated failure time model analysis with lognormal distribution. b Accelerated failure time model analysis with loglogistic distribution. c Accelerated failure time model analysis with 
exponential distribution. d Adjusted for sex, ethnicity, education level, household income level, smoking status and average daily physical activity. 
Table 4: Time ratios (TR) of the association between body composition phenotypes and survival years.  
 
 Participants ≥ 50 yearsa  Participants 50 - 70 yearsb Participants ≥ 70 yearsc 
          
 TR 95% CI p-value TR 95% CI p-value TR 95% CI p-value 
           
Crude model           
           
LA-HM 1.00 .  . 1.00 . . 1.00 . . 
           
LA-LM 0.95 0.92 - 0.99 0.008 0.94 0.89 - 0.99 0.01 0.94 0.72 - 1.23 0.64 
           
HA-HM 0.99 0.96 - 1.02 0.59 0.96 0.92 - 1.01 0.10 1.34 1.00 - 1.80 0.04 
           
HA-LM 0.95 0.92 - 0.99 0.01 0.92 0.87 - 0.98 0.007 1.05 0.78 - 1.41 0.76 
           
Adjusted modeld           
           
LA-HM 1.00 .  . 1.00 . . 1.00 . . 
           
LA-LM 0.95 0.92 - 0.99 0.007 0.93 0.88 - 0.98 0.01 0.96 0.71 - 1.30 0.79 
           
HA-HM 0.99 0.96 -1.02 0.37 0.95 0.90 - 1.00 0.03 1.42 1.07 - 1.89 0.01 
           
HA-LM 0.96 0.92 - 0.99 0.01 0.92 0.87 - 0.97 0.006 1.12 0.81 - 1.54 0.47   
LA is low adiposity, HA is high adiposity, LM is low adiposity and HM is high muscle mass. Complex survey design is taken into account for calculating the TR. a Accelerated failure time model 
analysis with lognormal distribution. b Accelerated failure time model analysis with loglogistic distribution. c Accelerated failure time model analysis with exponential distribution. d Adjusted 
for sex, ethnicity, education level, household income level, smoking status and average daily physical activity. 
 
 
Table 5: Time ratios (TR) for the association between TrFM/ASM ratio and survival years. 
 
 Participants ≥ 50 yearsa  Participants 50 - 70 yearsb Participants ≥ 70 yearsc 
           
 TR 95% CI  p-value TR 95% CI p-value TR 95% CI p-value 
           
Crude model           
           
< 15th centile 1.00 .  . 1.00 . . 1.00 . . 
           
15-84th centile 1.01 0.97 - 1.04  0.65 0.98 0.93 - 1.03 0.47 1.34 1.07 - 1.67 0.01 
           
85-94th centile 0.98 0.92 - 1.04  0.41 0.93 0.86 - 1.00 0.06 1.38 0.89 - 2.14 0.15 
           
>95th centile 0.94 0.88 - 1.00  0.05 0.89 0.82 - 0.95 0.002 1.41 0.85 - 2.32 0.17 
           
Adjusted modeld           
           
< 15th centile 1.00 .  . 1.00 . . 1.00 . . 
           
15-84th centile 1.00 0.96 - 1.04  0.96 0.95 0.89 - 1.01 0.10 1.43 1.14 - 1.79 0.003 
           
85-94th centile 0.98 0.92 - 1.04  0.43 0.91 0.84 - 0.99 0.03 1.44 0.91 - 2.28 0.11 
           
>95th centile 0.95 0.89 - 1.01  0.09 0.88 0.81 - 0.95 0.002 1.61 0.98 - 2.66 0.06 
            
TrFM is truncal fat mass and ASM is appendicular skeletal muscle mass. The groups are formed based on reference curves for the ratio between TrFM 
and ASM. Complex survey design is taken into account for calculating the TR. a Accelerated failure time model analysis with lognormal distribution. b 
Accelerated failure time model analysis with loglogistic distribution. c Accelerated failure time model analysis with exponential distribution. d Adjusted 
for sex, ethnicity, education level, household income level, smoking status and average daily physical activity. 
 
